EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Cormorant Asset Management, Lp Acquires 581,765 Shares

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) major shareholder Cormorant Asset Management, Lp acquired 581,765 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Thursday, April 18th. The stock was bought at an average cost of $18.03 per share, with a total value of $10,489,222.95. Following the acquisition, the insider now directly owns 7,475,000 shares of the company’s stock, valued at $134,774,250. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

EyePoint Pharmaceuticals Trading Down 4.0 %

EYPT opened at $16.95 on Tuesday. The stock has a market cap of $844.62 million, a PE ratio of -9.26 and a beta of 1.64. EyePoint Pharmaceuticals, Inc. has a 1 year low of $5.67 and a 1 year high of $30.99. The stock’s 50 day simple moving average is $23.43 and its 200-day simple moving average is $18.54.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative return on equity of 61.48%. The company had revenue of $14.03 million during the quarter, compared to analysts’ expectations of $8.71 million. During the same quarter in the prior year, the company posted ($0.61) EPS. Equities analysts forecast that EyePoint Pharmaceuticals, Inc. will post -1.73 earnings per share for the current fiscal year.

Institutional Trading of EyePoint Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EYPT. Jennison Associates LLC bought a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter valued at about $24,641,000. Franklin Resources Inc. increased its stake in EyePoint Pharmaceuticals by 11.8% in the fourth quarter. Franklin Resources Inc. now owns 4,640,651 shares of the company’s stock valued at $107,245,000 after purchasing an additional 488,206 shares in the last quarter. Federated Hermes Inc. raised its holdings in EyePoint Pharmaceuticals by 194.0% in the fourth quarter. Federated Hermes Inc. now owns 674,824 shares of the company’s stock worth $15,595,000 after purchasing an additional 445,289 shares during the period. UBS Group AG boosted its position in shares of EyePoint Pharmaceuticals by 487.6% during the third quarter. UBS Group AG now owns 526,848 shares of the company’s stock worth $4,210,000 after purchasing an additional 437,190 shares in the last quarter. Finally, First Turn Management LLC acquired a new position in shares of EyePoint Pharmaceuticals in the 4th quarter valued at $7,326,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on EYPT. HC Wainwright dropped their price target on EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, January 16th. JPMorgan Chase & Co. began coverage on EyePoint Pharmaceuticals in a research note on Monday, January 22nd. They issued an “overweight” rating and a $35.00 target price on the stock. Mizuho raised their price target on EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Finally, Capital One Financial reiterated an “overweight” rating on shares of EyePoint Pharmaceuticals in a research note on Friday, February 16th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.00.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.